Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 1
2012 1
2014 3
2015 1
2016 7
2017 23
2018 40
2019 53
2020 63
2021 78
2022 70
2023 18
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 32188412

307 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R, Rose M, Maurer A, Cassataro MA, Braunschweig T, Knüchel R, Vögeli TA, Ecke T, Eckstein M, Weyerer V, Esposito I, Ackermann M, Niegisch G, Gaisa NT; German Study Group of Bladder Cancer (DFBK e.V.). Morsch R, et al. BMC Cancer. 2020 Mar 18;20(1):230. doi: 10.1186/s12885-020-06727-2. BMC Cancer. 2020. PMID: 32188412 Free PMC article.
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F. Eckstein M, et al. Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5. Eur J Cancer. 2019. PMID: 30528808
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Schwamborn K, Ammann JU, Knüchel R, Hartmann A, Baretton G, Lasitschka F, Schirmacher P, Braunschweig T, Tauber R, Erlmeier F, Hieke-Schulz S, Weichert W. Schwamborn K, et al. Virchows Arch. 2019 Nov;475(5):599-608. doi: 10.1007/s00428-019-02610-z. Epub 2019 Jul 2. Virchows Arch. 2019. PMID: 31267201 Free PMC article.
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
Reis H, Serrette R, Posada J, Lu V, Chen YB, Gopalan A, Fine SW, Tickoo SK, Sirintrapun SJ, Iyer G, Funt SA, Teo MY, Rosenberg JE, Bajorin DF, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA. Reis H, et al. Am J Surg Pathol. 2019 Jul;43(7):920-927. doi: 10.1097/PAS.0000000000001264. Am J Surg Pathol. 2019. PMID: 31135485 Free PMC article.
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Vennapusa B, Baker B, Kowanetz M, Boone J, Menzl I, Bruey JM, Fine G, Mariathasan S, McCaffery I, Mocci S, Rost S, Smith D, Dennis E, Tang SY, Damadzadeh B, Walker E, Hegde PS, Williams JA, Koeppen H, Boyd Z. Vennapusa B, et al. Appl Immunohistochem Mol Morphol. 2019 Feb;27(2):92-100. doi: 10.1097/PAI.0000000000000594. Appl Immunohistochem Mol Morphol. 2019. PMID: 29346180 Free PMC article.
307 results